Ozon Pharmaceuticals has signed an agreement with Tecom Group for establishing its new manufacturing facility on a 150,700 sq ft area in Dubai Industrial City, the region’s leading industrial and logistics hub.

 

The new AED293 million ($79.7 million) facility, coming up at Dubai Industrial City, is being built in two phases and is set for complete operation by next year.

 

Ozon is the latest medical leader to join Dubai Industrial City, which is home to more than 1,000 local, regional, and international customers, including Standard Carpets, Himalaya Wellness, IFFCO Group, and Unilever and over 300 operational factories. 

 

The Phase 1 of the project will be developed at an investment of AED110 million and will have a production capacity of more than 300 million tablets a year. Upon completion, the facility will serve key markets in the GCC and regional countries such as Iraq, Morocco, Algeria, and Libya, reported Wam.

 

In the initial phase, 100 employees across specialisations such as quality assurance, pharmaceutical control, and manufacturing will work at the facility, featuring advanced medicine tracking systems to provide traceability and security through all stages of the product development lifecycle.

 

The musataha agreement was signed by Saud Abu Alshawareb, Executive Vice President of Industrial at Tecom Group, and Dr Mustafa Khalaf, General Manager at Ozon Pharmaceuticals, on the sidelines of Innoprom 2024 in Ekaterinburg in Russia.

 

The signing ceremony was attended by Dr Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade, Omar Al Suwaidi, Undersecretary of the Ministry of Industry and Advanced Technology, and Alexey Gruzdev, Deputy Minister of Industry and Trade of the Russian Federation.

 

"Localised medical manufacturing strengthens supply chains, response times, and self-sufficiency, all of which are essential levers to embed resilience in the healthcare sector," said Abu Alshawareb.

 

"Such socioeconomic security through the manufacturing sector is among the visions of Operation 300bn, Make it in the Emirates, and Dubai Economic Agenda ‘D33’ strategies, he stated.

 

Dr Khalaf said: "Our vision through the launch of this facility is to have a positive impact on the manufacturing and healthcare sectors in the UAE, the wider Middle East, and the CIS regions by ensuring a consistent supply of high-quality medicines."

 

"We also aim to foster technological innovation and elevate the standards of healthcare delivery in these regions," he added.-TradeArabia News Service